Lindbrook Capital, LLC Agios Pharmaceuticals, Inc. Transaction History

Lindbrook Capital, LLC

$1.09 Billion
Q4 2024

A detailed history of Lindbrook Capital, LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 163 shares of AGIO stock, worth $5,453. This represents 0.0% of its overall portfolio holdings.

Number of Shares

163

Previous 163 -0.0%

Holding current value

$5,453

Previous $7,000 28.57%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$41.19 - $49.72 $576 - $696	-14 Reduced 7.91%	163 $7,000
Q2 2024 Jul 31, 2024	BUY	$27.55 - $48.83 $826 - $1,464	30 Added 20.41%	177 $7,000
Q4 2023 Jan 31, 2024	SELL	$19.97 - $24.53 $199 - $245	-10 Reduced 6.37%	147 $3,000
Q3 2023 Oct 25, 2023	SELL	$24.36 - $28.18 $1,802 - $2,085	-74 Reduced 32.03%	157 $3,000
Q2 2023 Jul 28, 2023	BUY	$21.38 - $29.19 $2,907 - $3,969	136 Added 143.16%	231 $6,000
Q1 2023 Apr 26, 2023	SELL	$21.74 - $30.93 $1,173 - $1,670	-54 Reduced 36.24%	95 $2,000
Q4 2022 Jan 24, 2023	BUY	$24.81 - $31.52 $917 - $1,166	37 Added 33.04%	149 $0
Q3 2022 Nov 10, 2022	BUY	$19.51 - $34.14 $741 - $1,297	38 Added 51.35%	112 $3,000
Q2 2022 Aug 01, 2022	BUY	$17.06 - $31.42 $1,074 - $1,979	63 Added 572.73%	74 $2,000
Q1 2022 Apr 21, 2022	SELL	$26.68 - $34.81 $2,267 - $2,958	-85 Reduced 88.54%	11 $0
Q4 2021 Jan 18, 2022	SELL	$29.58 - $49.78 $1,153 - $1,941	-39 Reduced 28.89%	96 $3,000
Q4 2020 Jan 27, 2021	SELL	$33.21 - $46.54 $1,726 - $2,420	-52 Reduced 27.81%	135 $6,000
Q2 2020 Jul 27, 2020	BUY	$34.45 - $53.48 $1,791 - $2,780	52 Added 38.52%	187 $10,000
Q4 2019 Jan 27, 2020	BUY	$30.08 - $50.59 $4,060 - $6,829	135 New	135 $6,000

Others Institutions Holding AGIO

# of Institutions

234

Shares Held

58.3M

Call Options Held

403K

Put Options Held

469K

View Full List

About AGIOS PHARMACEUTICALS, INC.

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.83B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

More about AGIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Account

Lindbrook Capital, LLC Agios Pharmaceuticals, Inc. Transaction History